000			04244nam a22003615i 4500
001			82191
003			ES-MaUEC
005			20230207040400.0
007			cr nn 008mamaa
008			141118s2015 gw | s |||| 0|eng d
020			_a9783319099156
024	7		_a10.1007/978-3-319-09915-6 _2doi
050		4	_aQP572.L48 _b2015 EB
245	1	0	_aLeptin : _bRegulation and Clinical Applications _cedited by Sam Dagogo-Jack, MD.
260			_aCham, Switzerland _bSpringer _c2015
300			_a1 recurso en línea (XXIII, 287 páginas) _b48 ilustraciones, 27 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aDiscovery of leptin and elucidation of leptin gene expression -- Leptin receptors and mechanism of action -- Leptin interaction with brain orexigenic and anorexigenic pathways -- Measurement of circulating leptin and soluble leptin receptors -- Physiological and hormonal factors that influence leptin production -- Leptin, obesity and leptin resistance -- Leptin and intermediary metabolism: Focus on glucoregulation and lipid metabolism -- Leptin in acute stress -- Leptin and the kidney -- Leptin, immune function, and inflammation -- Leptin and bone -- Leptin, cell cycle, and cancer -- Leptin, the autonomic nervous system, and hypertension -- Dynamic leptin secretion in obesity and diabetes -- Leptin therapy of congenital leptin deficiency -- Leptin therapy in people with normal leptin gene -- Leptin therapy in patients with lipodystrophy and syndromic insulinÂ{u2973}istance -- Leptin therapy in women with hypothalamic amenorrhea -- Leptin therapy as a substitute for insulin replacement in experimental models of diabetes: Clinical implications in humans -- Novel combinatorial therapies involving leptin: Opportunities for mechanistic advances and therapeutic translation in human diseases.
520	3		_aTwenty years after its discovery, recombinant human leptin has been approved by the Food and Drug Administration for the treatment of patients with lipodystrophy.Â{u2967}ginning with a synthesis of the vast body of work on its discovery, dissection of mechanisms, and effects in experimental models , the focus of this book shifts to a consideration of the regulation and role of leptin in humans. The emphasis on human-level data is a unique feature of this book. The results of numerous studies indicate that leptin is indeed a regulated human hormone. Leptin provides a detailed account of the myriad physiological, hormonal, metabolic, immunological, mitogenic and inflammatory modulators and targets of leptin in a single volume. Next follows a comprehensive presentation of the therapeutic trials of recombinant leptin in patients with congenital leptin deficiency, lipodystrophy, hypothalamic amenorrhea, and other emerging areas, including leptin supplementation in leptin-replete subjects, leptin substitution for insulin in diabetic models, and novel combination regimens of leptin and other biogenic peptides. Unanswered questions and future directions in leptin research are highlighted in the Foreword by Dr. Jeffrey Friedman and throughout the volume. Identifying such questions helps direct research that could deepen understanding of the complex regulation of leptin under physiological and pathological conditions, a critical prerequisite to its rational deployment in the treatment of human disorders.
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
650		7	_aMetabolismo _xTrastornos _0 _2embne _9168790
650		7	_aEndocrinología _0 _2embne _9139372
650	2	7	_aEndocrinología _0 _2embne _9139372
700	1		_aDagogo-Jack, MD, Sam _eeditor literario _994946 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-09915-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12908319 _b10-10-17 _c10-02-16
988			_aSpringer_Medicine_2015
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0
945			_aQP572.L48 L478 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11575992 _z06-04-17
999			_c82191 _d82191 _x1